This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UROV Urovant Sciences (UROV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Urovant Sciences Stock (NASDAQ:UROV) 30 days 90 days 365 days Advanced Chart Get Urovant Sciences alerts:Sign Up Key Stats Today's Range$16.24▼$16.2450-Day Range$16.19▼$16.2452-Week Range$7.15▼$16.26VolumeN/AAverage Volume114,469 shsMarket Capitalization$531.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Read More Receive UROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address UROV Stock News HeadlinesXavier Creative House Appoints Jami Rogers as VP of Sales & MarketingNovember 4, 2024 | msn.comXavier Creative House Hires Jami Rogers as Vice President of Sales & MarketingOctober 29, 2024 | finance.yahoo.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 3 at 2:00 AM | American Alternative (Ad)Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromeApril 26, 2024 | finanznachrichten.dePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromeApril 26, 2024 | finance.yahoo.comA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsMarch 26, 2024 | finance.yahoo.comPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsDecember 6, 2023 | finance.yahoo.comPM360 Announces 2023 Trailblazer Award WinnersOctober 4, 2023 | finance.yahoo.comSee More Headlines UROV Stock Analysis - Frequently Asked Questions How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd. (NASDAQ:UROV) released its earnings results on Thursday, February, 11th. The company reported ($1.46) earnings per share for the quarter, topping analysts' consensus estimates of ($1.59) by $0.13. When did Urovant Sciences IPO? Urovant Sciences (UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). Company Calendar Last Earnings2/11/2021Today7/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UROV CIK1740547 Webwww.urovant.com Phone44-0-20-7400-3347FaxN/AEmployees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.74 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.90% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-8.55Miscellaneous Outstanding Shares32,743,000Free FloatN/AMarket Cap$531.75 million OptionableNot Optionable Beta2.36 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:UROV) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Urovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.